Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Equity Average (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Equity Average for 7 consecutive years, with -$35.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 79.88% to -$35.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$35.4 million, a 79.88% decrease, with the full-year FY2019 number at -$20.8 million, up 29.6% from a year prior.
  • Equity Average was -$35.4 million for Q4 2025 at Outlook Therapeutics, down from -$34.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$19.7 million in Q4 2024 to a low of -$41.4 million in Q1 2025.